Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484626 · ClinicalTrials.gov registry record · Phase 1
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
A Phase 1 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01484626: Clinical Trial Phase 1 study, sponsored by Loyola University.
NCT01484626 is a Phase 1 study that was terminated before completion, run by Loyola University. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01484626, a Phase 1 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma. The study will be conducted in two phases. Participants in phase I will receive 1 of 4 escalating doses of bendamustine. Once the maximum tolerated dose of bendamustine is determined, phase II of this trial will begin. Participants in phase II will receive the maximum tolerated dose of bendamustine in combination with standard of care chemotherapy.
Primary Outcome
The number of patients experiencing at least one toxicity at the lowest dose of bendamustine. A toxicity is defined as one or more of the following: Upper respiratory infection; anemia; thrombocytopenia; neutropenia; shortness of breath on exertion; decreased appetite; nausea; neuropathy; anxiety; arthritis; and hypercalcemia.
Interventions
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-05-05 |
| Est. Completion | 2014-06-18 |
| Phase | Phase 1 |
Why NCT01484626 stopped before completion
NCT01484626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Bendamustine is the first listed.
NCT01484626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01484626 about?
NCT01484626 is a clinical study titled "Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma". The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma. The study will be conducted in two phases. Participants in phase I will receive 1 of 4 escalatin...
What is the current status of trial NCT01484626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-05-05. Estimated completion is 2014-06-18.
What interventions are being tested in trial NCT01484626?
The interventions under investigation include: Bendamustine (DRUG).
Who is sponsoring clinical trial NCT01484626?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01484626's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI